Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
101-120 of 3,900 trials

Cirrhosis and Ascites: Personalized Human Albumin Treatment

We are studying a tailored approach to human albumin therapy for patients with liver cirrhosis and fluid buildup. The goal is to identify who may respond best to this treatment.

Liver Cirrhosis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementHepatologyInternal Medicine

Early Breast Cancer: Imlunestrant vs Standard Therapy

We are studying a new treatment called imlunestrant for patients with early breast cancer who have already received 2 to 5 years of standard therapy. The goal is to see if it helps reduce the risk of cancer returning compared to current treatments.

Breast Cancer>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Acute Leukemia: 177Lu-PentixaTher Treatment

We are testing a new radioligand therapy for patients with relapsed or refractory CXCR4+ acute leukemia. The study aims to evaluate its effectiveness in treating this challenging condition.

Acute Leukemia>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

Early Breast Cancer: Camizestrant vs. Standard Therapy

We are studying whether the new medication camizestrant can better prevent breast cancer recurrence in patients who have completed initial treatment. This trial involves individuals with ER+/HER2- early breast cancer at risk of returning after standard therapy.

ER+/HER2- Early Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Multiple Sclerosis: Rituximab vs. Ocrelizumab Study

We are comparing two treatments for relapsing-remitting multiple sclerosis to see if rituximab is as effective as ocrelizumab in preventing disease activity. This study also examines patient quality of life and other important factors.

Multiple Sclerosis1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesNeurology

COPD: Eosinophil-Guided Inhaled Corticosteroid Reduction

We are studying whether adjusting inhaled corticosteroid treatment based on eosinophil levels helps patients with severe COPD. We also want to see if low-dose Azithromycin can reduce hospital visits and improve overall health.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsMonitoring phase (IV)Standard MedicinesInternal MedicinePulmonology

Acute Lymphoblastic Leukaemia: ALLTogether Treatment Study

We are studying new treatment options for children and young adults aged 0-45 with newly diagnosed acute lymphoblastic leukaemia. The goal is to improve survival and quality of life through various interventions.

Acute Lymphoblastic Leukaemia>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

ANCA-Associated Vasculitis: Pioglitazone Treatment

We are studying whether adding pioglitazone to standard treatments can improve kidney function in patients with ANCA-associated vasculitis. The trial also looks at quality of life and potential side effects.

ANCA-associated Vasculitis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteNephrologyRheumatology

Semaglutide for Acute Ischemic Stroke

We are studying whether a new injection of semaglutide is safe and effective for non-diabetic patients right after an ischemic stroke. This trial aims to improve treatment options during this critical time.

Ischemic Stroke≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesCardiologyNeurology

Fanconi Anemia: Long-Term Study of RP-L102 Infusion

We are evaluating the long-term safety and health effects of a gene therapy infusion for patients with Fanconi Anemia. This study looks at blood health and potential risks over time.

Fanconi's AnemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost Reimbursement

Advanced Solid Tumors: ITF3756 Treatment Study

We are testing a new oral medication for patients with advanced solid tumors to see if it is safe and effective, both alone and with another treatment. This study aims to understand how well it works in combination with an anti-protein 4 agent.

Advanced Solid TumorsSafety phase (I)Oncology

Biliary Atresia: Long-term Study of Odevixibat

We are studying the long-term effects of odevixibat in children with biliary atresia to see if it helps improve liver health and overall growth. The trial also looks at the safety of this treatment over time.

Biliary Atresia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyPediatrics

Infantile-onset Pompe Disease: Cipaglucosidase Alfa/Miglustat Study

We are evaluating a new treatment for children under 18 with infantile-onset Pompe disease to see if it is safe and effective. This study includes both children who have and have not received previous enzyme replacement therapy.

Pompe's Disease (Infantile Onset)>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurologyPediatrics

Migraine Prevention: Atogepant for Kids

We are studying the long-term safety and tolerability of atogepant in children and teens aged 6 to 17 with migraines. This research aims to ensure the treatment is safe for young patients.

Migraine1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Episodic Migraine: Atogepant for Kids and Teens

We are studying the safety and effectiveness of Atogepant tablets for children and teens aged 6 to 17 with episodic migraines. This trial compares the medication to a placebo to see if it helps reduce migraine symptoms.

Episodic Migraine3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Ulcerative Colitis: GS-5290 Medication Study

We are testing a new medication for people with moderately to severely active ulcerative colitis to see if it helps improve symptoms better than a placebo. The study will assess various measures of clinical response and remission.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Understanding Pain in Parkinson's Disease: PET Imaging Study

We are exploring how the serotonin system affects pain in people with Parkinson's disease. This study compares those with and without pain to learn more about their experiences and brain activity.

Parkinson's Disease>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurology

Children's Experience After General Anesthesia: Sedation Study

We are examining how different sedative medications impact children's recovery after surgery. The goal is to see if these medications can help reduce anxiety and improve overall comfort.

General Anesthesia and Sedation6-12 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesInternal MedicineOtolaryngologyPediatrics

Arthritis from Cancer Immunotherapy: Tocilizumab Study

We are investigating whether adding tocilizumab to short-term glucocorticoids helps people with arthritis caused by cancer immunotherapy more than glucocorticoids alone. This study aims to improve arthritis control and patient outcomes.

Arthritis from Cancer TreatmentEfficacy phase (II)No PlaceboStandard MedicinesOncologyRheumatology

Migraine Relief: High-Flow Oxygen Therapy

We are studying whether high-flow oxygen therapy can help relieve migraine attacks in the emergency department. The trial also looks at its effects on related symptoms and overall patient experience.

Common Migraine1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNeurology